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Intramuscular injection of bacterially derived plasmid DNA results in the development of both humoral and cellular immune
responses against plasmid-encoded antigens. Immunostimulatory CpG sequences within bacterial DNA are thought to
enhance this process by stimulating the secretion of proinflammatory cytokines such as interferon g (IFNg) by cells of the
innate immune system. Although IFNg induction by CpG elements within plasmid DNA has been documented in vitro and
more recently in vivo, and coimmunization with plasmids expressing IFNg has been shown to enhance DNA-immunization-
induced immune responses, it is unclear if IFNg is necessary for successful DNA immunization. To address this issue, we
compared humoral and cellular immune responses in wild-type and IFNg-deficient mice vaccinated with a plasmid (pCMVNP)
expressing the nucleoprotein gene from the arenavirus lymphocytic choriomeningitis virus (LCMV). IFNg-positive (BALB/c)
and IFNg-negative (GKO) mice responded to DNA vaccination by the development of antigen-specific CD81 T cells, which
were detectable directly ex vivo by intracellular cytokine staining and comprised 0.7–2.5% of all CD81 T cells in the vaccinee.
DNA vaccines also induced virus-specific cytotoxic T lymphocytes (CTL), even in the absence of IFNg. DNA vaccination of
both mouse strains also was associated with a significant reduction in viral titers after LCMV challenge, indicating that, at
least in the presence of other immune effector mechanisms, IFNg is not required for induction of protective anti-viral
immunity by DNA immunization. No quantitative differences were observed in antiviral IgG levels among GKO and BALB/c
vaccinees, although GKO mice did exhibit a significant reduction of the IgG2a:IgG1 ratio, in agreement with the previously
documented requirement for IFNg in isotype switching to IgG2a. Immunized BALB/c mice produced similar levels of both
IgG1 and IgG2a, indicating a mixed Th1/Th2 response to intramuscular immunization with pCMVNP. These results show that
IFNg induction by bacterially derived plasmid DNA does not contribute to the magnitude of the antibody response and is not
required for the induction or short-term maintenance of DNA-induced CTL. However, IFNg is necessary for the development
of IgG2a antibodies that may be crucial for protection against some pathogens. © 1999 Academic Press
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Immunization with plasmid DNAs expressing for-
ign proteins provokes both cellular and humoral
mmune responses that are often of sufficient magni-
ude to provide the host with protective immunity
gainst viruses (Donnelly et al., 1997; Hassett and
hitton, 1996; Fu et al., 1999; Tolley et al., 1999; Whit-
on et al., 1999), bacteria (Barry et al., 1995; Uchijima
t al., 1998), parasites (Gurunathan et al., 1997), and
umors (Ciernik et al., 1996; Schirmbeck et al., 1996;
orr et al., 1997). Intramuscular injection of plasmid
NA in saline induces a Th1- or mixed Th1/Th2-type
mmune response, characterized by the development
f antigen-specific cytotoxic T lymphocytes (CTL), se-
um antibodies, and the secretion by antigen-specific
D41 T cells of IFNg (Th1) or IFNg and IL-4 (Th1/Th2).
uch attention has recently been focused on unmeth-
lated CpG motifs in bacterial (and bacterially derived)
NA. These motifs have nonspecific adjuvant activity;
1 To whom reprint requests should be addressed. Fax: (858) 784-
c380. E-mail: lwhitton@scripps.edu.
175hey interact directly with cells of the innate (Ballas et
l., 1996; Stacey et al., 1996; Oxenius et al., 1999) and
ntigen-specific (Krieg et al., 1995; Klinman et al., 1996;
xenius et al., 1999) immune systems, causing them to
roduce cytokines, including IL-12, IFNg, IFNa/b, and
umor necrosis factor-a (TNFa). Because IFNg is im-
ortant in controlling many virus infections and be-
ause recent papers have implicated IFNg in DNA-
nduced immune responses, we wished to determine if
his cytokine is essential for successful DNA vaccina-
ion. To do this, we immunized IFNg knockout (GKO)
ice with a plasmid expressing the nucleoprotein
ene from lymphocytic choriomeningitis virus (LCMV)
nd evaluated the development of anti-nucleoprotein
gG and CTL responses. Plasmid DNA was able to
rime both virus-specific IgG and CTL responses in
KO mice. We therefore conclude that stimulation of
FNg secretion by CpG motifs in plasmid DNA is not an
ssential component of a successful DNA vaccine. We
id, however, observe a profound decrease in the level
f IgG2a and an increase in IgG1 among GKO vaccine
ecipients, confirming that IFNg is required for the
nduction of IgG2a antibody responses after intramus-
ular plasmid administration.
0042-6822/99 $30.00
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176 HASSETT, ZHANG, AND WHITTONRESULTS
NA immunization induces antigen-specific CD81 T
ell responses in the absence of IFNg
We have previously shown that a DNA-encoded mini-
ene comprising only a CTL epitope can prime for
CMV-specific CTL responses (Rodriguez et al., 1998).
owever DNA immunization induces only low levels of
ytic CTL, and identification of lytic activity—as de-
cribed below—requires extensive in vivo or in vitro
estimulation, to amplify CTL activity to detectable levels.
herefore to directly demonstrate the presence of virus-
pecific CD81 T cells induced by pCMVNP, we used an
lternative technique that does not rely on lytic activity
nd allows antigen-specific cells to be detected directly
x vivo with minimal restimulation. This assay, intracel-
ular cytokine staining (ICCS), is described under Mate-
ials and Methods. In brief, mice were immunized with
FIG. 1. DNA immunization induces antigen-specific CD81 T cell res
mmunized with pCMV or pCMVNP as indicated and, 2 weeks later sple
ontrol for the assay, cells were analyzed from previously nonimmune
ithout the CTL epitope peptide and then were stained for CD8, IFNg, a
ated and evaluated for expression of IFNg (y axis) and TNFa (x axis).
n that quadrant as a percentage of all cells in that panel (all four qu
FNg1TNFa1 at 7 days p.i. In all cases, this number reflects the perc
eptide stimulation (i.e. in the equivalent “no pep” quadrant). Only perceCMV (negative control) or pCMVNP, and 2 weeks later dplenocytes were harvested, stimulated for 6 h, stained
or expression of CD8, IFNg, and TNFa, and analyzed by
low cytometry. As a positive control for the assay,
plenocytes were also analyzed from mice infected 7
ays previously with LCMV. As shown in Fig. 1, both
ALB/c and GKO mice mounted strong peptide-specific
D81 T cell responses easily detected 7 days p.i. At this
ime point, 41.5% of all CD81 T cells in a BALB/c spleen
ere virus specific, similar to published results (Murali-
rishna et al., 1998; Slifka et al., 1999). In GKO mice, the
D81 response to virus infection was reduced with only
.2% of CD81 T cells being detectable by TNFa staining.
s expected, no peptide-specific signal was seen in the
pper (IFNg1) quadrants in GKO mice. Importantly, pep-
ide-specific cytokine-producing CD81 T cells were eas-
ly detected in both BALB/c and GKO mice that had been
mmunized with pCMVNP. To our knowledge, this is the
irst direct ex vivo demonstration of DNA vaccine-in-
s in immunocompetent and in GKO mice. BALB/c or GKO mice were
were harvested and assayed for virus-specific responses. As positive
t 7 days p.i. (LCMV). All splenocytes were stimulated for 6 h with or
a as described under Materials and Methods. Live CD81 T cells were
ber in a “1 pep” dotplot quadrant indicates the number of CD81 cells
). For example, 13.2% of all CD81 T cells in the mouse spleen were
corrected for the extremely low background seen in the absence of
.0.1% above background are considered significant, and are shown.ponse
nocytes
mice a
nd TNF
A num
adrants
entageuced antigen-specific CD81 T cells, and representative
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177IFNg UNNECESSARY WITH DNA VACCINESesults are shown for three mice of each strain. In
ALB/c mice, 0.7–2.4% of all splenic CD81 cells were
eptide-specific 2 weeks after DNA immunization with
CMVNP. The majority of these cells were IFNg1TNFa2
upper left quadrants) or IFNg1TNFa1 (upper right quad-
ants). Although 10- to 20-fold lower than the proportion
nduced by virus infection, it is remarkable that a single
NA immunization can induce such a readily detectable
mmune response, visible as discrete populations of
ells. These cells were not visible in pCMVNP vaccinees
n the absence of peptide stimulation (Fig. 1, no pep), and
CMV-inoculated control mice showed essentially no
eptide-specific signal. DNA immunization also induced
irus-specific CD81 T cells in mice deficient in IFNg. As
hown in Fig. 1, 1.6–2.5% of all GKO splenic CD81 T cells
ere peptide specific (IFNg2TNFa1). These data show
nequivocally (i) that DNA immunization directly induces
ntigen-specific CD81 T cells and (ii) that this does not
equire IFNg.
ntramuscular immunization of plasmid DNA primes
TL activity in the absence of IFNg
In Fig. 1 we show that ICCS allows the detection of
ntigen-specific CD81 T cells induced by DNA immuni-
ation of normal and of GKO mice. However, we had no
vidence that the CD81 T cells induced by DNA vacci-
ation of GKO mice were capable of lysing infected
FIG. 2. DNA immunization induces antiviral CTL activity in the absen
ith plasmid DNA and subsequently challenged with LCMV 6 weeks lat
n vitro for lytic activity against Balb c17 (H-2d) target cells pulsed with
f 50:1 and 25:1 at 4 days postchallenge. As additional controls naı¨ve
ssayed either 4 or 7 days p.i. Each bar represents the data from anarget cells. Therefore we set out to determine whether mFNg was required for the induction or short-term main-
enance of CD81 T cell lytic activity initiated by DNA
accination. Many studies, in our lab and in other labs,
ave shown that lytic activity after DNA immunization is
ot sufficiently strong to be detected directly ex vivo by a
tandard cytotoxicity assay; instead, some form of sec-
ndary stimulation is required to expand these virus-
pecific CD81 T cells to a level where their lytic activity
an be identified. In the LCMV model, we employ a 4-day
n vivo secondary stimulation. Therefore, wild-type mice
BALB/c) or IFNg-deficient mice (GKO) were immunized
ith plasmid DNAs expressing the LCMV nucleoprotein
pCMVNP), a ubiquitinated form of the nucleoprotein
pCMVubNP) or a vector control (pCMV). Six weeks later
he mice were challenged with LCMV and 4 days post-
hallenge splenocytes from individual mice were tested
n vitro for lytic activity against MHC matched and mis-
atched target cells coated with an LCMV CTL epitope
eptide. As expected, non-DNA-vaccinated IFNg-posi-
ive (BALB/c) and -negative (GKO) mice showed evidence
f virus-specific CTL 7 days after infection (Fig. 2, no
NA d7). Thus as previously noted (Tishon et al., 1995)
he strong antigenic stimulation encountered during the
ourse of an acute virus infection can lead to the devel-
pment of CTLs in the absence of IFNg. In contrast, and
s expected, at 4 days p.i. LCMV-specific CTL responses
ere barely detectable in naı¨ve non-DNA-vaccinated
FNg. IFNg knockout (GKO) or normal (BALB/c) mice were immunized
scribed under Materials and Methods. Spleen samples were analyzed
oprotein-specific CTL epitope peptide, at effector to target (E:T) ratios
NA vaccinated mice from both strains were infected with LCMV and
al mouse.ce of I
er as de
a nucle
, non-Dice of either strain (Fig. 2, no DNA d4).
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178 HASSETT, ZHANG, AND WHITTONAccelerated CTL responses, which are evidence of
uccessful DNA immunization, were observed at 4 days
.i. in BALB/c and GKO mice that had been previously
accinated with either pCMVNP or pCMVubNP. Among
he pCMVNP vaccinees, CTL responses were detectable
n 75% (3/4) of the BALB/c and 50% (2/4) of the GKO mice
t this time point. Vaccination with pCMVubNP was
lightly more successful, as all of the BALB/c mice (4/4)
nd 75% (3/4) of the GKO mice were positive for lytic CTL
days p.i.; these data are consistent with the previous
emonstration by this laboratory of an enhancement in
TL responses after DNA immunization with pCMVubNP
Rodriguez et al., 1997). It is not known why a few mice
BALB/c and GKO) fail to respond to the DNA vaccines;
owever, this has been observed in all labs carrying out
CMV DNA immunization studies (Pedroza Martins et al.,
995; Yokoyama et al., 1995; Zarozinski et al., 1995) and is
urrently under investigation. As expected, virus-specific
TL were not detected at 4 days p.i. in mice of either
train vaccinated with vector alone (pCMV), showing that
he accelerated appearance of lytic CTL after virus infec-
ion did not result from a nonspecific adjuvant effect of
lasmid DNA. In all cases negligible lytic activity was
bserved when peptide pulsed MHC mismatched or
oninfected MHC matched target cells were used (data
ot shown). Thus the in vitro lytic responses observed in
ice vaccinated with pCMVNP or pCMVubNP were due
FIG. 3. CTL from DNA-vaccinated GKO mice can limit virus replication
or infectious virus on monolayers of Vero cells as described under Ma
ouse; closed triangles indicate the mean viral titers for each group. T
t 4 days p.i. in previously naı¨ve mice (no DNA, day 4).o MHC-specific, peptide-specific CTL. We conclude 2rom these data that plasmid DNA vaccines, like natural
iral infections, are able to induce antigen-specific CTL
n the absence of IFNg.
TL from DNA vaccinated GKO mice are effective
n limiting viral replication in vivo
Eradication of LCMV in vivo depends upon the devel-
pment of virus-specific CTL, the lytic activity of which is
rucial for clearance (Kagi et al., 1994; Walsh et al., 1994).
ecause DNA immunization of GKO mice primed LCMV-
pecific lytic CTL (Fig. 2), it appeared likely that these
ice also would be protected against virus challenge. To
etermine if this was indeed the case, spleen samples
rom the mice shown in Fig. 2 were assayed for the
resence of infectious LCMV. As shown in Fig. 3, at 4
ays p.i., in the absence of prior DNA inoculation, both
ouse strains contained high levels of infectious virus.
he nonspecific adjuvant activity of DNA had no mea-
urable effect on virus clearance because, at this time
oint, negative control (pCMV) vaccinees had titers sim-
lar to those animals that had received no DNA. However,
n both immunocompetent and GKO mice, prior success-
ul immunization with DNA vaccines carrying NP or ubNP
ed to markedly reduced virus titers at 4 days p.i. For
hese groups, each open circle (in Fig. 3) represents a
ouse in which CTL activity had been identified (see Fig.
. Spleen samples from the same animals shown in Fig. 1 were titrated
and Methods. Each open circle represents the data from an individual
izontal bar represents a 90% reduction compared to the average titerin vivo
terials
he hor). The horizontal bar in Fig. 3 represents a 90% reduc-
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179IFNg UNNECESSARY WITH DNA VACCINESion in LCMV titer compared to the level seen at 4 days
.i. in a previously naı¨ve animal. In both mouse strains,
ice successfully immunized with the NP or ubNP vac-
ines showed .90% reduction in viral titers at this time
oint. These results have high statistical significance,
evealed by comparing each of the NP and ubNP groups
eparately to the pCMV group, for each mouse strain. In
ALB/c mice, the P values resulting from these analyses
re ,0.01 and 0.003; in GKO mice, P , 0.02 and 0.006.
hus both pCMVNP and pCMV-ubNP are effective vac-
ines, with ubNP being somewhat more effective, as
reviously noted (Rodriguez et al., 1997). More impor-
antly, for the purpose of this study, we show that the CTL
mmunity induced by DNA vaccination of GKO mice is
iologically relevant. We conclude from these data that
TL are induced by DNA vaccines in the absence of
FNg (Fig. 2), and these CTL are effective in protecting
P-vaccinated, IFNg-deficient mice from LCMV (Fig. 3).
FNg is not required for the induction or maintenance
f virus-specific IgG
Bacterial DNA, and the CpG motifs therein, have been
hown to be polyclonal B cell activators (Krieg et al.,
995), and IFNg plays an important role in determining
gG class switching and isotype profiles (Snapper and
aul, 1987; Huang et al., 1993). We therefore investigated
he ability of DNA to induce humoral responses in the
bsence of IFNg. To determine the kinetics of the anti-
iral IgG response, BALB/c or GKO mice were immu-
FIG. 4. Lack of IFNg does not alter the kinetics of the IgG response
nduced by DNA immunization. Anti-LCMV IgG antibody endpoint titers
ere determined by ELISA from serum obtained from BALB/c or GKO
ice at 0, 2, 4 and 6 weeks post pCMVNP vaccination. Each bar
epresents the average endpoint titer 6 standard error from four se-
aopositive mice.ized with pCMVNP and bled at biweekly intervals and
ntiviral serum IgG endpoint titers were measured by
LISA. Within 2 weeks of vaccination, mice of both
trains showed a four- to fivefold increase in serum
nti-LCMV IgG (Fig. 4), and this level of IgG was main-
ained over the course of the next month in both IFNg-
ositive and -negative mice. In an additional experiment
onfirming the results of Fig. 4 (data not shown) at six
eeks after DNA immunization, all eight of the BALB/c
ice, and seven of eight of the GKO mice, had mounted
gG responses and there were no statistically significant
ifferences in the mean levels of anti-LCMV serum anti-
odies in GKO or BALB/c mice. Together these data
how that an inability to produce IFNg neither enhances
or inhibits the magnitude or the kinetics of the IgG
esponses to plasmid-encoded antigens.
ack of IFNg skews the antibody response induced
y DNA immunization
IFNg is involved in IgG class switching and enhances
gG2a responses while inhibiting IgG1 responses. We
herefore assessed the IgG isotype profiles in GKO and
ALB/c pCMVNP vaccinees (Fig. 5). All of the BALB/c
4/4) and three of four of the GKO mice were positive for
nti-LCMV IgG 6 weeks postvaccination, and the
mounts of total IgG present in each strain at this time
ere not significantly different (P 5 0.08), confirming the
esults shown in Fig. 4. However the levels of IgG1 were
reater in GKO mice than in BALB/c mice (P 5 0.024),
onfirming that the absence of IFNg permitted the devel-
pment of an enhanced IgG1 response. IgG2a was de-
ectable in only one of the GKO mice, and 3/4 BALB/c
ice mounted IgG2a responses. Thus after intramuscu-
ar DNA immunization, the overall IgG responses in GKO
nd BALB/c vaccinees are similar, but there is a quali-
ative difference in the distribution of IgG isotypes in the
FIG. 5. Absence of IFNg skews the DNA-induced antibody response
oward IgG2a. LCMV IgG-specific isotype end-point titers were deter-
ined by ELISA, as described under Materials and Methods, from
erum obtained from individual BALB/c or GKO mice 6 weeks post
CMVNP vaccination. The titers of individual animals are represented
s open circles, and the geometric mean titer for each group is shown
s a solid triangle.bsence of IFNg.
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180 HASSETT, ZHANG, AND WHITTONDISCUSSION
One of the major differences between DNA vaccina-
ion and other more conventional modes of vaccination is
he quantity of antigen present in the host after vaccine
dministration. Both live and killed vaccines would be
xpected to provide considerable amounts of antigenic
roteins either as a direct component of the vaccine
killed and subunit vaccines) or as a result of amplifica-
ion in vivo (live vaccines). In contrast, only minute
mounts of antigen are produced after DNA immuniza-
ion, and yet DNA vaccines are remarkably effective at
nducing both cellular and humoral immune responses.
thers have proposed that the success of DNA vaccines
ight be due, in part, to the immunostimulatory effects of
acterially derived DNA, which might facilitate the estab-
ishment of an immunologic milieu conducive to the de-
elopment of protective levels of antibodies and/or CTL.
he immunostimulatory effects of bacterial DNA are me-
iated by CpG dinucleotides, which are ;20 times more
ommon in bacterial DNA than in the DNA of higher
ukaryotes (Krieg et al., 1995). The sequences flanking
he CpG dinucleotide are important, and a consensus
otif 59RRCGYY39 (R 5 purine, Y 5 pyrimidine) has been
dentified. Oligonucleotides of this general structure bind
irectly to certain cells of the innate and antigen-specific
mmune system, such as macrophages, dendritic cells,
nd B (but not T) lymphocytes (Oxenius et al., 1999),
romoting the secretion of the proinflammatory (Th1)
ytokines IL-12, IL6, IL18, TNFa, IFNa, IFNb, and large
mounts of IFNg. Such oligonucleotides act as strong
djuvants for protein- or peptide-based immunogens
Davis et al., 1998; Moldoveanu et al., 1998) and may be
ffective even when administered without cognate anti-
en. They can greatly enhance innate immunity to the
acterium Listeria monocytogenes, probably by activat-
ng macrophages (Oxenius et al., 1999), and can suc-
essfully treat a normally lethal challenge with the pro-
ozoan Leishmania major (Zimmermann et al., 1998).
owever, CpG oligonucleotides, when administered
long with a plasmid DNA vaccine, do not improve the
accine-induced responses (Weeratna et al., 1998); in-
tead the sequence motifs appear to enhance immuno-
enicity only when cloned into the plasmid (Sato et al.,
996). One might imagine that greater quantities of plas-
id DNA would drive the immune response toward the
h1 phenotype, and this might be less evident if small
uantities of DNA were administered. Consistent with
his hypothesis, DNA injected by the intramuscular or
ntradermal routes often induces Th1 responses, while
he “gene-gun”—which employs ;100- to 1000-fold less
NA—and purified protein antigens often induce Th2
esponses (Raz et al., 1996; Leclerc et al., 1997). Although
his effect has been attributed to the quantity of DNA
noculated, it also has been suggested that the method if immunization, rather than the route or DNA quantity, is
he deciding factor (Feltquate et al., 1997).
Recent studies identify IFNg as an important mediator
f DNA-induced immune responses (Sur et al., 1999;
alker et al., 1999) and use IFNg as an indicator of the
mmunostimulatory capacity of bacterial DNA (Neujahr et
l., 1999). To determine whether or not IFNg is critical to
he success of a DNA vaccine, we immunized IFNg-
eficient mice with plasmids expressing the nucleopro-
ein of lymphocytic choriomeningitis virus. These plas-
ids contain 25-27 copies of the consensus motif and
hus, presumably, have the capacity to activate the innate
mmune system. We show here (Fig. 1) that DNA immu-
ization of normal mice induces CD81 T cell responses
emonstrable directly ex vivo and that similar responses
re induced by DNA immunization of mice deficient in
FNg. Thus IFNg is not required for successful DNA
mmunization, and any role played by CpG motifs cannot
equire IFNg. Several laboratories have shown that a
ingle intramuscular injection of plasmid DNA encoding
CMV nucleoprotein can effectively prime virus-specific
TL responses in mice (Pedroza Martins et al., 1995;
okoyama et al., 1995; Zarozinski et al., 1995; Hassett et
l., 1997). These accelerated lytic responses represent
n amplification of memory cytotoxic T cells originally
rimed by plasmid-expressed LCMV antigens and thus
re indicative of successful vaccination. Here we show
hat the development and short-term survival of plasmid
ntigen-primed, virus-specific CTL were unaffected by a
ack of IFNg (Fig. 2). These data conclusively show that
ecretion of IFNg by elements of the innate immune
ystem in response to CpG motifs in plasmid DNA is not
equired for the successful induction of CTL by DNA
accines. We next evaluated the in vivo effects of these
ells against virus challenge. Protective immunity
gainst LCMV is mediated by lytic CD81 T cells and is
ependent on the major cytolytic protein perforin, in the
bsence of which mice are unable to clear the virus (Kagi
t al., 1994; Walsh et al., 1994). However, LCMV-specific
ffector T cells and memory T cells also produce IFNg in
esponse to T-cell receptor stimulation. The role of IFNg
n determining the outcome of acute LCMV infection is
omewhat controversial. Studies using monoclonal anti-
odies to block/deplete this cytokine suggest that repli-
ation of LCMV Armstrong, the virus used in our studies,
s increased in the absence of IFNg, (Moskophidis et al.,
994), and transgenic knockout (GKO and IFNg receptor
o) studies revealed at most a minor effect (Muller et al.,
994; Tishon et al., 1995). Analyses of infectious virus
resent in the spleens of DNA immunized mice 4 days
ostchallenge demonstrated that IFNg-deficient, DNA-
mmunized mice can limit the ability of LCMV to replicate
n vivo as effectively as can DNA immunized immuno-
ompetent mice (Fig. 3). The similarity in titers in nonim-
une IFNg-positive and -negative mice at 4 days p.i.ndicates that IFNg secretion by elements of the innate
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181IFNg UNNECESSARY WITH DNA VACCINESmmune system may not significantly affect the ability of
CMV to replicate in vivo during the early phases of the
nfection; therefore the protective effect seen at this time
oint in DNA-immunized GKO mice most probably re-
ults from the lytic activity of the CTL identified in Fig. 2.
hus in an otherwise immunocompetent mouse, IFNg is
ot required for the induction of protective immunity by a
NA vaccine.
The efficacy of many antimicrobial vaccines depends
argely upon the induction of antibody responses. We
how here that DNA vaccination in the absence of IFNg
esulted in qualitative, but not quantitative, differences in
ntiviral IgG responses. Although IFNg can promote both
olyclonal and specific B-cell activation and antibody
ecretion, we detected no statistically significant de-
rease in the amount of antigen specific serum IgG from
to 6 weeks post plasmid administration in GKO mice
Fig. 4). However the IgG1 response in GKO vaccinees
as enhanced (Fig. 5), in agreement with previous stud-
es (Snapper and Paul, 1987; Huang et al., 1993). We
onclude that overall antibody responses to DNA vac-
ines do not require the IFNg-inducing activity of bacte-
ial DNA. Therefore any effects of the CpG motifs—
hich we do not directly evaluate here—are unlikely to
e mediated solely by IFNg.
In summary, although IFNg production by elements of
he innate immune system has been shown by others to
e induced in vitro and in vivo by CpG motifs present in
acterial and plasmid DNAs, it is not required for suc-
essful induction of effective antiviral CTL or antibody
esponses to DNA vaccines.
MATERIALS AND METHODS
ice
Homozygous IFNg knockout (GKO) mice (H-2d) were
riginally obtained from Dr. T. Stewart at Genentech (San
rancisco, CA) (Dalton et al., 1993). In all breeding pairs,
nd in randomly selected progeny, the presence of the
eomycin resistance cassette within the IFNg gene was
onfirmed by PCR analyses of genomic DNA. BALB/c
ice (H-2d) were obtained from the Scripps Research
nstitute animal facility. All animals were bred and
oused at the Scripps Research Institute animal facility
nd used between 6 and 16 weeks of age.
NA immunizations
To examine CTL induction, humoral responses, and
rotective immunity, mice were injected in the anterior
ibialis muscle with a single 50-mg dose of plasmid DNA
1 mg/ml, in saline). Plasmids used were the parent vec-
or (pCMV) alone, and pCMV containing the full-length
CMV nucleoprotein gene (pCMVNP) or a ubiquitinated
orm thereof (pCMVubNP). The construction of these
lasmids has been previously described (Yokoyama et al., 1995; Rodriguez et al., 1997). Plasmids were propa-
ated in Escherichia coli using standard techniques and
urified using a Qiagen EndoFree plasmid purification kit
Qiagen, Chatsworth, CA).
ntracellular cytokine staining
T cells respond to antigen contact by rapid expression
f cytokines such as IFNg and TNFa. These cytokines
re normally rapidly secreted from the T cell; so to
nhance the detectability of responding T cells, antigen
timulation is carried out in the presence of the Golgi
nhibitor brefeldin A, which prevents cytokine secretion
nd leads to their intracellular accumulation in respond-
ng T cells. These cells then can be permeabilised,
tained using fluorescently labeled cytokine-specific an-
ibodies, and detected on a FACS machine. For the stud-
es reported here, BALB/c and GKO mice were immu-
ized with pCMV or with pCMVNP (100 mg in each
nterior tibialis muscle), and 2 weeks later their spleens
ere harvested, and single cell suspensions of spleno-
ytes were prepared. Cells (2 3 106) were incubated for
h in 200 ml of RPMI containing 50 mM 2-mercaptoetha-
ol and 2 mg/ml brefeldin A in the presence or absence
f 1027 M peptide corresponding to the immunodominant
-2d restricted LCMV NP CD81 T cell epitope (NP118-126,
equence RPQASGVYM). After stimulation, the cells
ere washed with PBS 1 5% FBS, stained overnight with
n anti-mouse CD8 cychrome-conjugated antibody
Pharmingen, San Diego CA), washed with PBS 1 5%
BS, fixed in cold PBS 1 2% formaldehyde, and perme-
bilized with Cytofix/cytoperm (Pharmingen). Intracellu-
ar cytokines were stained with FITC-labeled antibody
pecific for mouse IFNg or PE-labeled antibody specific
or mouse TNFa (Pharmingen). Stained cells were ac-
uired on a FACScan flow cytometer (200,000-500,000
vents per sample) and analyzed using CELLQUEST
oftware (Becton Dickinson, San Jose, CA).
nalysis of LCMV-specific CTL
Mice were immunized with DNA as described above
nd 6-8 weeks later were intraperitoneally infected with
CMV (2 3 105 pfu, Armstrong strain.) Spleens were
emoved 4 days p.i. and immediately assayed for in vitro
ytolytic activity using a standard chromium release as-
ay. Briefly, a single-cell suspension was created by
entle Dounce homogenization, followed by incubation
ith 0.83 M NH4Cl to lyse erythrocytes. Spleen cells
ere washed twice in complete Dulbecco’s modified
agle’s medium (DMEM) (DMEM plus 5% bovine serum,
0 mM L-glutamine, 50 U penicillin G, 50 mg streptomycin
ulfate per liter) and resuspended in complete RPMI
RPMI plus 10% fetal bovine serum (FBS), 20 mM L-
lutamine, 50 U penicillin G, 50 mg streptomycin sulfate
er liter] at a concentration of either 1 3 107 cells/ml (for
n effector-to-target [E/T] ratio of 50:1) or 5 3 106 cells/ml
(
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182 HASSETT, ZHANG, AND WHITTONfor an E/T ratio of 25:1). Target cells [MHC matched
albc 17 (H-2d) or MHC-mismatched MC57 (H-2b) cells]
ere left untreated or were pulsed with a peptide corre-
ponding to an H-2d immunodominant epitope within the
ucleoprotein (NP118-126) and were incubated for 2 h
ith 51Cr (50 mCi/1 3 106 cells). Effector and target cells
ere incubated together in triplicate wells at both E/T
atios for 5 h in a total volume of 200 ml per well, after
hich 100 ml of supernatant was harvested and assayed
or released radioactivity. Specific chromium release was
alculated for each well using the formula [(sample re-
ease 2 spontaneous release) 3 100 4 (total release 2
pontaneous release)]. Values for total and spontaneous
elease were obtained by incubation of target cells with
r without 1% N-P40, respectively.
valuation of in vivo protection
Spleen samples from the same mice used in the in
itro CTL assay described above were snap frozen in
iquid nitrogen and stored at 270°C. Each sample was
eighed then homogenized in 1 ml of complete medium
99 [medium 199 plus 10% fetal bovine serum (FBS), 20
M L-glutamine, 50 U penicillin G, 50 mg streptomycin
ulfate per liter, Gibco/BRL, Gaithersburg, MD]. Plaque
ssays of serially diluted spleen homogenates were
one on Vero cell monolayers (routinely maintained in
omplete medium 199). The cell monolayers were fixed 3
ays postinoculation in 25% formaldehyde, 13 PBS for
h and then stained with crystal violet.
easurement of serum IgG
Serum was prepared from whole blood from mice at
arious times postimmunization. Ninety-six-well plates
Falcon 3912 Microtest III flexible assay plates, Becton
ickinson, Oxnard, CA) were coated with 100 ml of
enograffin-gradient-purified LCMV in PBS (200 ng total
rotein/well) as antigen. After overnight incubation at
oom temperature, the unbound antigen was removed
nd the wells were blocked with blocking buffer [3%
ovine serum albumin (BSA fraction V, Sigma, St. Louis,
O), 0.2% Tween 20 in 13 PBS] and washed with wash
uffer (0.1% Tween 20, 13 PBS). The serum samples
ere serially diluted in blocking buffer and added to the
arget plate (100 ml/well). After a 1-h incubation at room
emperature, the liquid was aspirated and the wells were
ashed three times with wash buffer. Bound IgG1, IgG2a,
r total IgG was detected using horseradish peroxidase
onjugated anti-mouse secondary antibodies of the ap-
ropriate isotype specificity (Southern Biotechnology,
irmingham, AL; used at a 1-4000 dilution, 100 ml per
ell). After a 1-h incubation at room temperature, the
econd antibody was removed and the wells were
ashed three times with wash buffer. Horseradish per-
xidase activity was measured by incubation for 30 min
ith 100 ml of the substrate o-phenylenediamine dihy- Hrochloride in urea hydrogen peroxide (Sigmafast OPD
ablets Sigma, St. Louis, MO) followed by the addition of
N HCl (100 ml per well). Absorbance at 492 nm was
easured using a Titertek multiscan plus (Titertek, Flow
aboratories, Mclean, VA). The end-point titers, which
epresent an optical density value of 3 standard devia-
ions above the mean value of wells incubated with a
ooled control serum from nonimmunized mice, were
alculated on serially diluted serum samples by linear
egression.
tatistical analysis
Student’s t test was performed to determine the sta-
istical relatedness of data from groups of GKO and
ALB/c vaccinees using SigmaPlot statistical analysis
oftware (SPSS Corp., Chicago, IL).
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